InvestorsHub Logo
Followers 24
Posts 883
Boards Moderated 0
Alias Born 02/28/2017

Re: reverse_long post# 20875

Sunday, 11/24/2019 6:10:17 AM

Sunday, November 24, 2019 6:10:17 AM

Post# of 54913
Sec did a full review of Pred a number of months ago. It’s called a form 10! 300 plus pages.
Deloitte did a full review prior to taking the company on last month.
Wilson sonsini review everything the company does and have one of their founders on PREDs advisory board. CLSA spent 5 months reviewing everything prior to engagement.
Preeclampsia foundation (backed by gates foundation) did a full review
ThermoFisher did full review before global collaboration
ASRM did full review prior to asking Pred to present 2 of the 3 keynote speeches at asrm
ESRE did a full review prior to asking pred to give keynote so each at ESRE
Joh Sorintino did full review prior to leaving management in pFE

However I’m sure your review and discussions are much more detailed and carry more weight.

Longs, the turn is coming, look for stock to dry up like Friday , Monday/Tuesday the same would be telling. The company is executing and whether the company is making 10m a quarter or 20m a quarter is irrelevant. If you bought the stick for the stemcell revenues then sell as that’s not what the company’s about. Most don’t see the real value, the most comprehensive genetic database in the world. That’s the value and that’s why we will see multiple collaborations. Endometriosis is just step 1, what the can do with endo, they can do with anything. That’s why thermo are there.

Tough few months but watch for fireworks